High throughput Screening (HTS) is a key element of the early drug discovery process and essential for the identification of molecules with suitable target-specific properties to develop a promising drug. Listen to Dr Florian Fuchs, Laboratory Head Screening at NUVISAN-ICB and Dr Stefan Prechtl, Principal Scientific Advisor at CELLIMA Scientific Services, reflecting on the impact of High Content Imaging and its use during preclinical stage.
